Retrospective Comparison of Early versus Late Treatment with Fluticasone Propionate/Salmeterol After an Asthma Exacerbation

References

• National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma – Summary Report 2007. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf. Accessed date May 5, 2010.
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2009. Available at: www.ginasthma.org. Accessed March 3, 2011.
   Google Scholar
• Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005; 60:730–734.
   PubMed Web of Science ®Google Scholar
• Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol 1999; 82:383–389.
   PubMed Web of Science ®Google Scholar
• Greening AP, Ind PW, Northfield M, Shaw G, . Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219–224.
   PubMed Web of Science ®Google Scholar
• Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, Ducharme FM, . Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; 19(4):1–179.
   Google Scholar
• Murray JJ, Church NL, Anderson WH, Bernstein DI, Wenzel SE, Emmett A, Rickard KA, . Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allerg Asthma Proc 1999; 20(3):173–180.
   PubMed Web of Science ®Google Scholar
• Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481–1488.
   PubMed Web of Science ®Google Scholar
• Pearlman DS, White MV, Lieberman AK, Pepsin PJ, Kalberg C, Emmett A, Bowers B, Rickard KA, Dorinsky P, . Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol 2002; 88:227–235.
   PubMed Web of Science ®Google Scholar
• Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, Rickard KA. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120:423–430.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106:1088–1095 [Erratum. J Allergy Clin Immunol 2001; 107:614].
   PubMed Web of Science ®Google Scholar
• Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103:1075–1080.
   PubMed Web of Science ®Google Scholar
• Complete Prescribing Information and Medication Guide for ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder). Available at: http://www.advair.com. Accessed November 10, 2008.
   Google Scholar
• O’Connor RD, O’Donnell JC, Pinto LA, Wiener DJ, Legorreta AP. Two-year retrospective economic evaluation of three dual controller therapies used in the treatment of asthma. Chest 2002; 121:1028–1035 [published correction appears in Chest 2002; 122:387].
   PubMed Web of Science ®Google Scholar
• Stempel DA, O’Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs.J Allergy Clin Immunol 2002; 109:433–439.
   PubMed Web of Science ®Google Scholar
• Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113:245–251.
   PubMed Web of Science ®Google Scholar
• Delea TE, Hagiwara M, Stanford RH, Stempel DA. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clin Ther 2008; 30(3):560–571.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15–26.
   PubMed Web of Science ®Google Scholar
• Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008; 149:33–42.
   PubMed Web of Science ®Google Scholar
• Deyo RA. Adapting a comorbidity index for use with ICD-9-CM administrative data: a response. J Clin Epidemiol 1993; 46:1085–1090.
   Google Scholar
• Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41–55.
   Web of Science ®Google Scholar
• Rubin DB. Estimating causal effects from large datasets using propensity scores. Ann Intern Med 1997; 127:757–763.
   PubMed Web of Science ®Google Scholar
• Allison PA. Survival Analysis Using the SAS system: A Practical Guide. Cary, NC: SAS Institute, Inc., 1995; 304 p.
   Google Scholar
• Akazawa M, Biddle AK, Stearns SC. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clin Ther 2008; 30(1):1003–1016.
   Google Scholar